22
May

Shanghai drug developer Cellular Biomedicine reported some positive results from a small study of its in-development cancer immunotherapy, sending its shares up more than 15% on Friday.

…read more

Source: China’s Cellular Biomedicine spikes on early CAR-T data

    

0 No comments